Pregnancy, sex and hormonal factors in multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 5, 2014, Pages 527-536

  Miller, David H ^a   Fazekas, Franz ^b   Montalban, Xavier ^c   Reingold, Stephen C ^d   Trojano, Maria ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Scientific and Clinical Review Associates LLC   (United States)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

hormones; Pregnancy; sex

Indexed keywords

CORTICOSTEROID; ESTROGEN; SEX HORMONE; BETA INTERFERON; ESTRIOL; GLATIRAMER; NOMEGESTROL ACETATE; TESTOSTERONE;

BREAST FEEDING; CONCEPTION; DEMOGRAPHY; DISEASE COURSE; FERTILITY; MEDLINE; MENOPAUSE; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; PUBLICATION; REVIEW; ANIMAL; FEMALE; HUMAN; MALE; METABOLISM; ONSET AGE; PREGNANCY COMPLICATIONS; RISK FACTOR; SEX DIFFERENCE; TIME; CLINICAL TRIAL (TOPIC); DELIVERY; DISEASE ASSOCIATION; HORMONAL THERAPY; MANAGED CARE; PATIENT COUNSELING; PATIENT MONITORING; PHARMACEUTICAL CARE; PUERPERIUM; RISK BENEFIT ANALYSIS;

AGE OF ONSET; ANIMALS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREVALENCE; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 84899045261     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513519840     Document Type: Review

References (100)

1. Baker D, Gerritsen W, Rundle J, et al. Critical appraisal of animal models of multiple sclerosis. Mult Scler. 2011 ; 17: 647-657
2. Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol. 2012 ; 33: 105-115
3. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012 ; 8: 255-263
4. Polanczyk MJ, Zamora A, Subramanian S, et al. The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol. 2003 ; 163: 1599-1605
5. Polanczyk MJ, Hopke C, Huan J, et al. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol. 2005 ; 170: 85-92
6. Matsushita T, Yanaba K, Bouaziz JD, et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008 ; 118: 3420-3430
7. Papenfuss TL, Powell ND, McClain MA, et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011 ; 186: 3346-3355
8. Bodhankar S, Wang C, Vandenbark A, et al. Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol. 2011 ; 41: 1165-1175
9. Bodhankar S, Vandenbark AA, Offner H. Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17-oestradiol-receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells. Immunology. 2012 ; 137: 282-293
10. Bodhankar S, Offner H. GPR30 forms an integral part of E2-protective pathway in experimental autoimmune encephalomyelitis. Immunol Endocr Metab Agents Med Chem. 2011 ; 11: 262-274
11. Matejuk A, Hopke C, Vandenbark AA, et al. Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J Immunol. 2005 ; 174: 2387-2395
12. Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: A therapeutic target for myelin repair in chronic demyelination. Brain. 2013 ; 136: 132-146
13. Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptor- in astrocytes. Proc Natl Acad Sci U S A. 2011 ; 108: 8867-8872
14. Crawford DK, Mangiardi M, Song B, et al. Oestrogen receptor beta ligand: A novel treatment to enhance endogenous functional remyelination. Brain. 2010 ; 133: 2999-3016
15. Saijo K, Collier JG, Li AC, et al. An ADIOL-ER-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell. 2011 ; 145: 584-595
16. Garay L, Deniselle MC, Meyer M, et al. Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis. Brain Res. 2009 ; 1283: 177-185
17. Hussain R, El-Etr M, Gaci O, et al. Progesterone and nestorone facilitate axon remyelination: A role for progesterone receptors. Endocrinology. 2011 ; 152: 3820-3831
18. Ziehn MO, Avedisian AA, Dervin SM, et al. Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease. J Neurosci. 2012 ; 32: 12312-12324
19. Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 2006 ; 5: 932-936
20. Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: A systematic review. Neurology. 2008 ; 71: 129-135
21. Trojano M, Lucchese G, Graziano G, et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One. 2012 ; 7: e48078
22. Kotzamani D, Panou T, Mastorodemos V, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology. 2012 ; 78: 1728-1735
23. Boström I, Stawiarz L, Landtblom AM. Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). Mult Scler. 2013 ; 19: 46-52
24. Chao MJ RS, Herrera BM, Orton SM, et al. MHC transmission: Insights into gender bias in MS susceptibility. Neurology. 2011 ; 76: 242-246
25. Sellner J, Kraus J, Awad A, et al. The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors. Autoimmun Rev. 2011 ; 10: 495-502
26. Holmqvist P, Hammar M, Landtblom AM, et al. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril. 2010 ; 94: 2835-2837
27. Nielsen NM, Jørgensen KT, Stenager E, et al. Reproductive history and risk of multiple sclerosis. Epidemiology. 2011 ; 22: 546-552
28. Ponsonby AL, Lucas RM, van der Mei IA, et al. Offspring number, pregnancy, and risk of a first clinical demyelinating event: The AusImmune Study. Neurology. 2012 ; 78: 867-874
29. Magyari M, Koch-Henriksen N, Pfleger CC, et al. Reproduction and the risk of multiple sclerosis. Mult Scler. 2013 ; 19: 1604-1609
30. Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler. 2013 ; 19: 351-358
31. Hedström AK, Hillert J, Olsson T, et al. Reverse causality behind the association between reproductive history and MS. Mult Scler. 2013 ;:
32. Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol. 2013 ; 149: 219-224
33. Hellwig K, Schimrigk S, Beste C, et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009 ; 61: 65-68
34. Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry. 2012 ; 83: 796-802
35. Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012 ; 72: 682-694
36. Robertson N, Deans J, Fraser M, et al. Recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996 ; 119: 449-455
37. Robertson NP, O'Riordan JI, Chataway J, et al. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet. 1997 ; 349: 1587-1590
38. Ebers GC, Yee IM, Sadovnick AD, et al. Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol. 2000 ; 48: 927-931
39. Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: Population based study. BMJ. 2005 ; 330: 120-124
40. Fiddes B, Wason J, Kemppinen A, et al. Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol. 2013 ; 73: 714-720
41. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 ; 296: 2832-2838
42. Mirzaei F, Michels KB, Munger K, et al. Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann Neurol. 2011 ; 70: 30-40
43. Office of Dietary Supplements National Institutes of Health. Dietary Supplement Fact Sheet: Vitamin D, http://ods.od.nih.gov/factsheets/VitaminD- HealthProfessional/ (24June2011, accessed 4 September 2013).
44. McCombe PA, Greer JM. Female reproductive issues in multiple sclerosis. Mult Scler. 2012 ; 19: 392-402
45. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998 ; 339: 285-291
46. Ramagopalan S, Yee I, Byrnes J, et al. Term pregnancies and the clinical characteristics of multiple sclerosis: A population based study. J Neurol Neurosurg Psychiatry. 2012 ; 83: 793-795
47. Koch M, Uyttenboogaart M, Heersema D, et al. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 ; 80: 676-678
48. d'Hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010 ; 81: 38-41
49. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007 ; 188: 1447-1474
50. Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: Part 1, evidence-based review and recommendations. AJR Am J Roentgenol. 2012 ; 198: 778-784
51. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013 ; 19: 835-843
52. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: Therapeutic considerations. J Neurol. 2013 ; 260: 1202-1214
53. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000 ; 62: 385-392
54. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: A prospective observational study. Mult Scler. 2009 ; 15: 1037-1042
55. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon- exposure in multiple sclerosis. Neurology. 2010 ; 75: 1794-1802
56. Sandberg-Wollheim M, Alteri E, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler. 2011 ; 17: 423-430
57. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: Experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012 ; 5: 247-253
58. Tomczyk S, Sperling B. Pregnancy outcomes in patients exposed to intramuscular interferon beta-1a (IM IFNB 1a). Neurology. 2013 ; 80: S30.006
59. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology. 2005 ; 65: 802-806
60. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology. 2012 ; 79: 1130-1135
61. Buchwalder PA, Buclin T, Trinchard I, et al. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000 ; 20: 857-866
62. Fragoso YD, Finkelsztejn A, Kaimen-Maciel DR, et al. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: A retrospective, multicentre case series. CNS Drugs. 2010 ; 24: 969-976
63. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: A prospective observational multicentric study. BMC Neurol. 2012 ; 12: 124
64. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011 ; 17: 958-963
65. Cristiano L, Bozic C, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Registry. Mult Scler. 2012 18 ;: P275
66. Geissbühler Y, Butzkuiven H, Hernández-Diaz S, et al. Multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry: Preliminary results. Neurology. 2013 ; 80: P02.134
67. Gold R, Phillips JT, Havrdova E, et al. BG-12 (dimethyl fumarate) and pregnancy: Preclinical and clinical data from the clinical development program. Neurology. 2013 ; 80: P02.129
68. FDA prescribing information TYSABRI, http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/125104s0576lbl.pdf (2012, accessed 4 September 2013).
69. FDA prescribing information GILENYATM, http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/022527s008lbl.pdf (2012, accessed 4 September 2013).
70. FDA prescribing information AUBAGIO, http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/202992s000lbl.pdf (2012, accessed 4 September 2013).
71. Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler. 2007 ; 13: 975-980
72. Martinelli V, Colombo B, Dalla Costa G. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler. 2013 ;:
73. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010 ; 257: 580-583
74. Teratogenic effects of AEDs while pregnant. NICE Guideline: The Epilepsies 2012, pp.511-533. http://www.nice.org.uk/nicemedia/live/13635/57784/ 57784.pdf (2012, accessed 4 September 2013).
75. Baclofen pregnancy and breastfeeding warnings. Drug Information Online: Drugs.com. http://www.drugs.com/pregnancy/baclofen.html (accessed 4 September 2013).
76. Oxybutinin pregnancy and breastfeeding warnings. Drug Information Online: Drugs.com. http://www.drugs.com/pregnancy/oxybutynin.html (accessed 4 September 2013).
77. Amantadine pregnancy and breastfeeding warnings. Drug Information Online: Drugs.com. http://www.drugs.com/pregnancy/amantadine.html (accessed 4 September 2013).
78. Clonazepam pregnancy and breastfeeding warnings. Drug Information Online: Drugs.com. http://www.drugs.com/pregnancy/clonazepam.html (accessed 4 September 2013).
79. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register 73: 104 (29May2008): pp.30831-30868, www.gpo.gov/fdsys/pkg/FR-2008-05-29/ content-detail.html (accessed 2 September 2013).
80. Dahl J, Myhr KM, Daltveit AK, et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005 ; 65: 1961-1963
81. Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology. 2009 ; 73: 1831-1836
82. van der Kop ML, Pearce MS, Dahlgren L, et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol. 2011 ; 70: 41-50
83. Lu E, Zhao Y, Zhu F, et al. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology. 2013 ; 80: 447-452
84. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse. Brain. 2004 ; 127: 1353-1360
85. Pastò L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: The Italian cohort study. BMC Neurol. 2012 ; 12: 165
86. de Seze J, Chapelotte M, Delalande S, et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. 2004 ; 10: 596-597
87. Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004 ; 251: 1133-1137
88. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler. 2007 ; 13: 900-908
89. Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011 ; 77: 145-150
90. Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009 ; 66: 958-963
91. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002 ; 52: 421-428
92. Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: A pilot study. Arch Neurol. 2007 ; 64: 683-688
93. Pozzilli C, De Giglio V, Barletta F, et al. Efficacy and safety of oral contraceptives as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon b-1a: A multicenter, randomized investigator-run clinical trial. Mult Scler. 2012 ; 18: S15
94. Alonso A, Clark CJ. Oral contraceptives and the risk of multiple sclerosis: A review of the epidemiologic evidence. J Neurol Sci. 2009 ; 286: 73-75
95. Vukusic S, El-Etr M, Ionescu I, et al. The POPARTMUS French-Italian multicentric trial of Post-Partum Progestin and Estriol in Multiple Sclerosis: Final results. Mult Scler. 2012 ; 18 (S4). 45
96. Bove RM, Healy B, Augustine A, et al. Effect of gender on late-onset multiple sclerosis. Mult Scler. 2012 ; 18: 1472-1479
97. Lebrun C, Le Page E, Kantarci O, et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012 ; 18: 1297-1302
98. Koch-Henriksen N, Stenager E, Laursen B. The use of epidemiological multiple sclerosis registers in research: The Danish MS Registry. Acta Neurol Scand. 2012 ; 126 (195). 7-12
99. Myhr KM, Grytten N, Torkildsen Ø, et al. A need for national registries and international collaborative research in multiple sclerosis. Acta Neurol Scand. 2012 ; 126 (195). 1-3
100. A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (Estriol in MS), http://clinicaltrials.gov/show/ NCT00451204 (11July2013, accessed 4 September 2013).